Investor Contacts

Sumit Goel

Company Secretary and Compliance Officer

Fortis Healthcare Limited
Fortis Hospital, Sector 62, Phase – VIII,
Mohali, Punjab  - 160062

Tel. No : +91-172-5096001
Fax No : +91-172-5096002

Mr. Ravi Rajagopal



Ravi Rajagopal is currently leading a plural career comprising Advisory and Board roles in addition to being associated with a number of charitable organisations. He is Chairman of Fortis Healthcare, India’s second largest listed company in healthcare, where IHH, Asia’s largest healthcare company is the major strategic shareholder. He is Independent Director and Audit Chair of Airtel Africa plc, UK, Africa’s second largest telecoms provider. His most recent appointment is Chairman and Independent Director of Catalyst Housing Limited, a top ten affordable housing company in the UK. Additionally, Ravi is Chairman for JM Financial Services, Singapore, which is a wholly owned subsidiary of JM Financial, India. For six years up to 31 March 2021, Ravi was Audit Chair of the Audit and Risk Committee for Vedanta Resources, UK, which was a FTSE 150 company until it de-listed itself in 2018. He has been an Association Member of BUPA since 2015 and, in 2018, he became a Trustee for the Science Museum Foundation, London.

Ravi has had an extensive career spanning 35 years working in large consumer goods companies including Diageo plc where he held several senior roles. Up to the time he took retirement, he was the Global Head of M&A at Diageo. His experience included working in many markets across the world in both a strategic and operational capacity.

Ravi is involved with various charitable activities: He is Chair of an Advisory Board in India for a project responsible for building and operating 4,000 childcare centres across northern India; and he is a Trustee of a group of four schools in Chennai, India that teaches over 1,100 underprivileged children free of cost.

Ravi has lectured on Behavioural Economics at the Said Business School at Oxford University and Imperial College, London.

Interests include tennis, cricket, music and reading.


Dr Ashutosh Raghuvanshi

Managing Director & CEO


Dr Ashutosh Raghuvanshi, is a cardiac surgeon turned management leader. After completing his MS in general surgery from MGIMS, Dr Ashutosh went on to do MCH in Cardiac surgery from the University of Bombay. Over the last 26 years, he has been associated with the Bombay Hospital, Apollo Hospitals, Vijaya Heart foundation and Manipal Heart Foundation. He is credited with the establishment of Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, where he joined as Director in 2000 and is today one of the largest Multispecialty Hospitals in Eastern India.

Before joining Fortis, he was last working with Narayana Health as Vice Chairman, Managing Director & Group CEO and was responsible for the operations of all the group hospitals across India and internationally.


Mr. Dilip Kadambi

Non-Executive Director


Over 24 years of leadership experience in various multinational organisations across both financial and healthcare institutions. Self-motivated leader with a variety of skillsets in areas such as investor relations, capital raising, corporate finance, strategy & business development, change management, mergers & acquisitions, financial reporting, revenue cycle management, group procurement and healthcare operations. Results-driven leader, team player and someone who constantly seeks to learn.


Dr. Farid Bin Mohamed Sani

Non-Executive Director


Dr. Farid re-joined Khazanah in December 2018 after serving as Chief Strategy Officer of UEM Group. Prior to that, he was with Telekom Malaysia from 2012 to 2017. Dr. Farid first joined Khazanah in July 2004 and stayed until 2011. He was previously a consultant at McKinsey & Co. He holds a Bachelor’s and Master’s degree in Chemical Engineering, as well as PhD in Chemical Engineering, all three from the University of Cambridge.


Mr. Indrajit Banerjee

Independent Director


lndrajit Banerjee, aged about 62 years, is a Chartered Accountant and has a corporate career spanning over 35 years. Over the last 20 years he has played a key role in senior leadership positions, principally in Ranbaxy, Cairn India, Lupin and Indal, dealing with unique business criticalities which led to the organisations realising their potential values.

He has a B. Com. (Hons) degree from St. Xavier's College, Kolkata. In his early career at Brooke Bond India Ltd and Indian Aluminium Co ltd (Indal), his focus was on establishing sound financial controls in complicated business environment which also facilitated businesses to improve their competitive position. Since then, he has played the role of CFO/Executive Director in companies that experienced difficult business situations of varying nature in complex shareholding situations.

Between 1982 and 1999 he was at Indal, of which the final two years he was Chief Financial Officer, where he played a key role in the strategy formation and risk management in the company during the transformation stage. He joined Lupin ltd in 2002, where he addressed the critical liquidity challenges faced by the company and led the entry of a set of private equity investors that helped re-brand the company. In 2005, he joined Cairn India ltd, where he guided the financing of the country's largest greenfield upstream onshore oil and gas development project which was the first large project of its size and complexity in India. He was also President and CFO, and a Member of the Executive Committee, at Ranbaxy Laboratories Ltd between 2011 and 2015, where he helped the company sustain itself through its most challenging times and played a critical role in the process leading to the merger of the company with Sun Pharma, later leading the integration of businesses and processes of the merged entity post-merger.

Since November 2015 he has engaged in certain specific management consultancy services, including business structuring and planning; management of growth situations; management of crisis situations through cash flow monitoring, prioritisation of operational requirements and bank relationship management; financing of working capital and establishment of Risk Management processes in multi-business and multi-regional organisations; business and financial process integration for existing organisations as well as for merging entities.


Mr. Joe Sim

Non-Executive Director


As the Chief Executive Officer of Malaysia Operations Division, Joe provides strategic direction and leadership for Parkway Pantai’s integrated healthcare businesses in Malaysia, which includes a network of 15 Gleneagles and Pantai hospitals and ancillary services such as Pantai Integrated Rehab and Pantai Premier Pathology.

Joe has more than 17 years’ experience in the healthcare industry and was the winner of the Leading CEO Award by Singapore Human Resources Institute in 2014. Prior to joining Parkway Pantai in June 2017, he was Group Deputy Chief Executive of National University Healthcare System in Singapore, where he had also served as Chief Operating Officer and Chief Executive Officer of National University Hospital. He also held the roles of Chief Corporate Development Officer, acting Chief Information Officer and acting Chief Executive Office for new ventures with the National Healthcare Group in Singapore.

Joe began his career with the Singapore Administrative Service, building up a robust portfolio at the Ministry of Finance, Community Development Council and Ministry of Defence. In 2000, he founded a company that developed business-to-business trading hubs before joining the private sector where he was responsible for developing thought leadership, concepts and innovations on next-generation revenue agency for Accenture. Between 2008 and 2015, Joe was also an adjunct lecturer at Nanyang Business School, during which he was recognised with a Teacher of the Year Award. He was also an Adjunct Associate Professor at the National University of Singapore’s School of Public Health and Business School before he joined Parkway Pantai.

Joe graduated with First Class Honours in Bachelor of Arts in Electronic and Information Science from Cambridge University and holds a Master in Public Administration from Harvard University.


Mr. Joerg Ayrle

Non Executive Director


Mr. Joerg Ayrle was appointed the Group Chief Financial Officer of IHH Healthcare Berhad (IHH) on 1 February 2021. With a wealth of international experience from United States, Germany, Singapore, China and Thailand, he will be responsible for providing financial leadership and strategic guidance for IHH and its operations and the business plan development. In his role, Joerg will ensure effective management of resources, safeguard shareholders' interests and steer financial and management reporting, treasury, tax and investor relations functions and support the companies M&A activities.

Prior to joining IHH, Mr. Ayrle was the GCFO of Thai Union Group and steered the Company's financial transformation journey, winning multiple awards including Best CFO Asia by Corporate Treasurer in 2016.

He also had a successful career with tech giants Osram and Siemens. Most notably, he was Chief Financial Officer & Treasurer of Osram Sylvania, USA, and Managing Director of Corporate Finance Mergers, Acquisitions & Post Closing (ASIA) for Siemens, China.

Academic / Professional Qualification(s)

Master of Business Administration major in Finance & Controlling, Marketing, Finance-Mathematics, University of Augsburg, Germany


Dr. Kelvin Loh

Non-Executive Director


Dr Kelvin Loh was appointed Chief Executive Officer (Designate) and Executive Director of IHH Healthcare on 1 July 2019 and will assume the position as its Managing Director and Chief Executive Officer on 1 January 2020. He provides strategic direction and leadership for overall operations within IHH and its key operating subsidiaries – Parkway Pantai, Acibadem Healthcare, Fortis Healthcare and IMU Health. Today, IHH Healthcare offers a full spectrum of integrated services including a strong stable of 83 hospitals and more than 15,000 licensed beds in 12 countries.

An experienced healthcare executive with strong track record of delivery, Dr Loh has extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing people. He is also deeply familiar with the healthcare operating context in different countries across Asia.

Prior to joining IHH Healthcare, Dr Loh was with Columbia Asia Group where he oversaw its healthcare business comprising 28 hospitals across four countries in Asia as Chief Executive Officer since 2017.

Dr Loh spent the early years of his career as a practicing general physician. Driven by a passion for healthcare systems improvement, he embarked on the management track in the public healthcare sector and widened his healthcare portfolios to include clinical services development, hospital planning and hospital management. In 2008, he joined IHH Healthcare where he served nine years in numerous senior management roles, including as Chief Executive Officer of Singapore Operations Division where he steered the group’s integrated healthcare businesses in Singapore.

Dr Loh holds a Bachelor of Medicine and Bachelor of Surgery and a Master of Business Administration from the National University of Singapore.



Ms. Shailaja Chandra

Independent Director


Ms. Shailaja Chandra has spent over 15 years in health sector and was a Secretary in the Ministry of Health & Family Welfare, Government of India and later she was appointed as first women Chief Secretary of Delhi.

Ms. Shailaja Chandra has been a career civil servant ( a member of the Indian Administrative Service,) for 38 years followed by a series of post-retirement assignments carrying executive responsibilities. During her long service career in the Central Government, she was posted over three tenures with the Ministries of Defence, Power and Health. At the state level, Ms. Chandra was posted across the country in Maharashtra, Manipur, Goa, Delhi and the Andaman & Nicobar Islands.

Since retirement Ms Chandra has held Board/ Management Committee level positions under the Government, the NGO sector as well as listed Indian companies.

She is a prolific writer and is regularly invited as a policy analyst by the print and electronic media to comment on matters of Governance, Health, Gender and current developments in Delhi, the capital of India. She has been invited several times to Chair or speak at International conferences organised by OECD as well as by Indian Universities, think tanks and health related forums.


Ms. Suvalaxmi Chakraborty

Independent Director


Suvalaxmi Chakraborty, aged about 52 years, is a Chartered Accountant and has 28 years of experience in the field of financial services and banking. She has featured in the Fortune India List of 50 most powerful women in business. .

She held several positions at ICICI Ltd and ICICI Bank between 1989 and 2006, including General Manager for Corporate Banking and Head of Rural, Micro-banking and Agri Business. She was Director on the Board of Fixed Income Money Markets and Derivatives Association (FIMMDA) for over 2 years and headed the working committee (New Products) in FIMMDA (representing ICICI). She launched and ran the commercial banking business of Barclays Bank in India from 2007 to 2010, after which she was Chief-Executive Office for the Indian operations of State Bank of Mauritius from 2010 to 2013. In 2014, she was also Advisor for Transwarranty Finance Ltd and Positron Consulting Services, with advisory assignments spanning debt syndication, Mergers & Acquisitions and capital raising for midmarket corporates, among others.

Currently she serves as an Independent Director for Magma HDI General Insurance Company Ltd, and Caspian Impact Investments Pvt Ltd. She is also serving on the board of RGVN (North East) Microfinance Ltd as a nominee director. She is Co-Founder and Director of Espandere Advisors Private Ltd, which is a Business Advisory and Transaction Advisory services provider in the Banking & Finance, Agriculture & Rural, Infrastructure and Manufacturing sectors. She is also Advisor for Fullerton India Credit Company Ltd, which is a 100% step down subsidiary of Temasek Holdings (Pte) Ltd, Singapore.

She has a B. Com. (Hons) degree from Calcutta University and in 1999 completed the Financial Investment Technology Program of the Berkeley Program in Finance at HAAS School of Business at University of California, Berkeley, California. In 2002 she participated in the Leading Change and Organizational Renewal Program at the Graduate School of Business, Stanford University, California, and she has also participated in the 'Women on Corporate Boards' initiative initiated by FICCI Centre for Corporate Governance.



Mr. Takeshi Saito

Non Executive Director (Additional)


Appointed to the Board of IHH Healthcare Berhad (IHH) in 2019, Mr Takeshi Saito was an alternate director to Mr Satoshi Tanaka and Mr Koji Nagatomi, former Directors of IHH, between June 2015 and March 2019. He also serves on the Boards of a few IHH subsidiaries. Mr Saito currently serves as Chief Executive Officer (CEO) of MBK Healthcare Management Pte Ltd (MHM), a wholly-owned subsidiary of Mitsui & Co., Ltd (Mitsui) based in Singapore, which manages the healthcare assets within the portfolio of Mitsui.

Preceding his appointment as CEO of MHM, he served as General Manager of Healthcare Business 1st Department in Healthcare Business Division of Mitsui. In 2017, he was an Executive Assistant to a Representative Director and Executive Vice President of Mitsui. Between 2015 and 2016, he was the General Manager of the Provider Network Department, Medical Healthcare Business Division 1, Consumer Service Business Unit of Mitsui and also sat on the Board and Executive Committee of Parkway Pantai Limited, a wholly-owned subsidiary of IHH, as an alternate director. In 2011, Mr Saito was seconded to Parkway Group Healthcare as Vice President of Strategic Planning, following his appointment as Director of the Medical Healthcare Business Department at Mitsui, where he led the investment in IHH.

Prior to this in 2007, Mr Saito was appointed Manager of the Strategic Planning/Business Development Department of the Life Science Division at Mitsui, which subsequently became the Medical Healthcare Division in 2008.

Academic / Professional Qualification(s)

Bachelor of Political Science, Keio University, Japan Master of Business Administration, Kellogg School of Management Northwestern University


Request A Media Interaction


  1. Ms. Lynette Joy Hepburn Brown has resigned from the Company with effect from April 11, 2017.
  2. Mr. Ravi Umesh Mehrotra has resigned from the Company with effect from April 12, 2017.
  3. Mr. Sunil Godhwani has vacated his office of director with effect from August 4, 2017.
  4. Ms. Shradha Suri Marwah has resigned from the Company with effect from November 14, 2017
  5. Mr. Malvinder Mohan Singh and Dr. Shivinder Mohan Singh have resigned
    from the Company with effect from February 8, 2018.
  6. Ms. Joji Sekhon Gill has resigned from the Company with effect from March 7, 2018.
  7. Dr. Preetinder Singh Joshi resigned with effect from March 19, 2018
  8. Mr. Pradeep Ratilal Raniga resigned with effect from March 22, 2018
  9. Lt. Gen. Tejinder Singh Shergill, Mr. Harpal Singh and Ms. Sabina Vaisoha resigned w.e.f. May 20, 2018
  10. Dr. Brian William Tempest was removed from the Board w.e.f. May 22, 2018
  11. Mr. Rohit Bhasin resigned with effect from June 26, 2018
  12. Dr. Tan See Leng resigned with effect from September 27, 2019
  13. Dr Chan Boon Kheng resigned with effect from October 31, 2019
  14. Mr. Chintamani Aniruddha Bhagat has resigned with effect from December 2, 2019
  15. Mr Low Soon Teck resigned with effect from June 4, 2020


Feedback Form